Company · founded 2010
Epigen Biosciences (United States)
San Diego, United States · epigenbiosciences.com
- Citations, last 5 years
- 79
- Works, last 5 years
- 8
- h-index
- 22
- Scientists listed
- 1
- Grants since 2016
- 28
Grants received
2025–2026 · research · R41
Novel Methods for Nicotinic Receptor Modulation in the Treatment of Post-Operative Pain
Daniel S Mcgehee · Epigen Biosciences (United States) · funded by National Institutes of Health
2024–2026 · research · R43
Novel Product Formulation toModulate Alpha7 Nicotinic Receptors for Therapy in Stroke Recovery
Ann Marie Stowe · Epigen Biosciences (United States) · funded by National Institutes of Health
2023–2025 · research · R43
New Therapy for the Treatment of Primary Biliary Cholangitis.
Merrill E Gershwin · Epigen Biosciences (United States) · funded by National Institutes of Health
2021–2024 · research · R43
Evaluation of Alzheimers disease experimental small molecule therapeutics in the models of Amyotrophic lateral sclerosis
Satheesh B Ravula · Epigen Biosciences (United States) · funded by National Institutes of Health
2021–2025 · research · R44
Candidate selection of a LPAR1 antagonist for therapeutic application in NASH
Rohit Kohli · Epigen Biosciences (United States) · funded by National Institutes of Health
2021–2023 · research · R43
Lead candidate identification of LPAR1 antagonists for therapeutic application in NASH
Fabio Cohen Tucci · Epigen Biosciences (United States) · funded by National Institutes of Health
2021–2023 · research · R44
Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy
Graham Beaton · Epigen Biosciences (United States) · funded by National Institutes of Health
2021–2025 · research · R44
Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy
Graham Beaton · Epigen Biosciences (United States) · funded by National Institutes of Health
2021–2026 · research · R44
Candidate selection of a LPAR1 antagonist for therapeutic application in NASH
Rohit Kohli · Epigen Biosciences (United States) · funded by National Institutes of Health
2020–2022 · cooperative agreement · U18
Novel modulators of ÃÂñ7 nAChRs as treatments for nicotine reward
Graham Beaton · Epigen Biosciences (United States) · funded by National Institutes of Health
2020–2021 · research · R43
Assessment of a selective kinase inhibitor in pre-clinical models of NASH
Fabio Cohen Tucci · Epigen Biosciences (United States) · funded by National Institutes of Health
2020–2022 · research · R43
Novel agents for idiopathic pulmonary fibrosis
Cory M Hogaboam · Epigen Biosciences (United States) · funded by National Institutes of Health
2019–2022 · research · R43
Therapeutic in Situ Analgesic Implant for improved Oral-Facial Post-Operative Pain Outcomes
Robert M Caudle · Epigen Biosciences (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Assessment of LPA1R antagonists in animal models of NASH
Kevin Bacon · Epigen Biosciences (United States) · funded by National Institutes of Health
2018–2021 · research · R43
New Approach to Atopic Dermatitis
Satheesh B Ravula · Epigen Biosciences (United States) · funded by National Institutes of Health
2017–2022 · research · R44
Administrative supplement for Novel therapy for Fragile X syndrome
Alysson R. Muotri · Epigen Biosciences (United States) · funded by National Institutes of Health
2017–2025 · research · R44
Novel therapy for Fragile X syndrome
Alysson R. Muotri · Epigen Biosciences (United States) · funded by National Institutes of Health
2017–2019 · research · R41
Novel therapy for Fragile X syndrome
Alysson R. Muotri · Epigen Biosciences (United States) · funded by National Institutes of Health
2017–2023 · research · R44
Novel therapy for Fragile X syndrome
Alysson R. Muotri · Epigen Biosciences (United States) · funded by National Institutes of Health
2017–2020 · research · R41
Novel therapy for Fragile X syndrome
Alysson R. Muotri · Epigen Biosciences (United States) · funded by National Institutes of Health
2017–2019 · research · R41
Novel therapy for Fragile X syndrome
Alysson R. Muotri · Epigen Biosciences (United States) · funded by National Institutes of Health
2017–2020 · research · R41
Novel Treatment for Traumatic Brain Injury
Fabio Cohen Tucci · Epigen Biosciences (United States) · funded by National Institutes of Health
2016 · research · R44
Development of novel agents for the treatment of renal fibrosis adminstrative supplement
Michael J. Caplan · Epigen Biosciences (United States) · funded by National Institutes of Health
2012–2021 · research · R44
Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease
Kevin Ron Nash · Epigen Biosciences (United States) · funded by National Institutes of Health
2012–2021 · research · R44
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis
Kumar Sharma · Epigen Biosciences (United States) · funded by National Institutes of Health
2012–2021 · research · R44
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis
Kumar Sharma · Epigen Biosciences (United States) · funded by National Institutes of Health
2012–2024 · research · R44
Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease
Kevin Ron Nash · Epigen Biosciences (United States) · funded by National Institutes of Health
2012–2023 · research · R44
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis
Kumar Sharma · Epigen Biosciences (United States) · funded by National Institutes of Health
